Company: CRVO
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001437749-25-007829
Chunk: 91

Company: CervoMed Inc.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 1A
Chunk 91
---
 be limited liquidity in the trading market for the Company’ s common stock, and the market price of its common stock may drop in the future.

The market price of the Company’s common stock may be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been volatile. Some of the factors that may cause the market price of the Company’s common stock to fluctuate include among others:

  the ability of the Company or its partners to develop product candidates and conduct clinical trials that demonstrate such product candidates are safe and effective;  

  the ability of the Company or its partners to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;  

  failure of any of the Company’s product candidates to demonstrate safety and efficacy, receive regulatory approval and achieve commercial success;  

  failure by the Company to maintain its existing third-party license, manufacturing and supply agreements;  

  failure by the Company or its licensors to prosecute, maintain, or enforce its intellectual property rights;  

  changes in laws or regulations applicable to the Company’s product candidates;  
 ──────────────────────────────────────────────────────────────────────────────────

  any inability to obtain adequate supply of product candidates or the inability to do so at acceptable prices;  

  adverse regulatory authority decisions;  

  introduction of new or competing products by the Company’s competitors;  

  failure to meet or exceed financial and development projections the Company may provide to the public;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────

  the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;  

  announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by the Company or its competitors;  

67

  disputes or other developments relating to proprietary rights, including patents, litigation matters, and the Company’s ability to obtain intellectual property protection for its technologies;  

  additions or departures of key personnel;  

  significant lawsuits, including intellectual property or stockholder litigation;  

  if securities or industry analysts do not publish research or reports about the Company, or if they issue an adverse or misleading opinions regarding its business and stock;  

  changes in the market valuations of similar companies;  
 ──────────────────────────────────────────────────────────

  general market or macroeconomic conditions;  

  sales of its common stock by the Company or its stockholders in the future;  

  the trading volume of the Company’s common stock;  

  the